Not Yet Recruiting

NCT Number: NCT07704970

QLESP Block for Pain Control in Robotic Partial Nephrectomy

The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are:

1. Does QLESP reduce the total amount of opioid pain medicine participants need in the first 48 hours after surgery? 2. Does QLESP lower pain scores and improve recovery quality after surgery? Researchers will compare participants who receive QLESP block to participants who receive the same numbing medicine injected only at the surgical wound sites.

Participants will:

1. Be randomly assigned to receive either QLESP or local wound injection before surgery. 2. Have a patient-controlled pain pump for 48 hours after surgery. 3. Complete pain scores and recovery quality questionnaires at 2, 6, 12, 24, 48, and 72 hours after surgery. 4. Be followed until hospital discharge.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Renal Cell Carcinoma (Kidney Cancer) Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Nerve Block Neurologic Manifestations Pain Pain, Postoperative Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Pain Signs and Symptoms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

Location contact

You-nian Xu

CONTACT

[email protected]

+8613657263415

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged 18 to 75 years
Scheduled for elective robot-assisted partial nephrectomy (RAPN)
American Society of Anesthesiologists (ASA) physical status I to III
Body mass index (BMI) 18 to 35 kg/m²
Voluntarily signed informed consent form Able to understand pain scoring and use of patient-controlled analgesia (PCA)

Exclusion criteria

Language, communication, or comprehension barriers
Infection at the intended puncture site
Coagulopathy or bleeding diathesis
Known allergy or contraindication to local anesthetics or opioids
Use of analgesic medications within the past 3 months
Peripheral neuropathy
Severe cardiac, hepatic, or renal dysfunction
Pregnancy or breastfeeding
Refusal to participate in the study

Treatment and study plan

ropivacaine (local infiltration)

Drug

Ultrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL injected between the erector spinae muscle and the transverse process at L2 level, followed by 15 mL injected between the quadratus lumborum and psoas major muscles) after induction of general anesthesia.

Ropivacaine

Drug

Local wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.

Primary outcomes

Cumulative Opioid Consumption at 48 Hours Postoperatively

Time frame: From the end of surgery to 48 hours postoperatively.

Cumulative opioid consumption measured at 48 hours after surgery

Study contacts

Contact information is provided by the study sponsor or research team.

Xi Wu

CONTACT

[email protected]

+8615871715431

Sponsors and collaborators

Lead sponsor

Huazhong University of Science and Technology

Other

Registry information

Official study title

Ultrasound-Guided L2 Level QLESP Block for Postoperative Analgesia in Robot-Assisted Partial Nephrectomy: A Prospective Randomized Controlled Trial

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Jul 15, 2026
Registry last updated: Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting